Your browser doesn't support javascript.
loading
H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial.
Mearns, Helen; Geldenhuys, Hennie D; Kagina, Benjamin M; Musvosvi, Munyaradzi; Little, Francesca; Ratangee, Frances; Mahomed, Hassan; Hanekom, Willem A; Hoff, Søren T; Ruhwald, Morten; Kromann, Ingrid; Bang, Peter; Hatherill, Mark; Andersen, Peter; Scriba, Thomas J.
Afiliación
  • Mearns H; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, South Africa.
  • Geldenhuys HD; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, South Africa.
  • Kagina BM; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, South Africa.
  • Musvosvi M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, South Africa.
  • Little F; Department of Statistical Sciences, University of Cape Town, South Africa.
  • Ratangee F; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, South Africa.
  • Mahomed H; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, South Africa.
  • Hanekom WA; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, South Africa.
  • Hoff ST; Statens Serum Institut, Copenhagen, Denmark.
  • Ruhwald M; Statens Serum Institut, Copenhagen, Denmark.
  • Kromann I; Statens Serum Institut, Copenhagen, Denmark.
  • Bang P; Statens Serum Institut, Copenhagen, Denmark.
  • Hatherill M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, South Africa.
  • Andersen P; Statens Serum Institut, Copenhagen, Denmark.
  • Scriba TJ; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, South Africa. Electronic address: Thomas.scriba@uct.ac.za.
Vaccine ; 35(1): 132-141, 2017 01 03.
Article en En | MEDLINE | ID: mdl-27866772
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oligodesoxirribonucleótidos / Oligopéptidos / Proteínas Bacterianas / Aciltransferasas / Linfocitos T CD4-Positivos / Adyuvantes Inmunológicos / Vacunas contra la Tuberculosis / Antígenos Bacterianos Tipo de estudio: Clinical_trials Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Vaccine Año: 2017 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oligodesoxirribonucleótidos / Oligopéptidos / Proteínas Bacterianas / Aciltransferasas / Linfocitos T CD4-Positivos / Adyuvantes Inmunológicos / Vacunas contra la Tuberculosis / Antígenos Bacterianos Tipo de estudio: Clinical_trials Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Vaccine Año: 2017 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Países Bajos